U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
[mark one]
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended:
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from ______________ to ______________
Commission File Number
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of | (IRS Employer |
incorporation or organization) | Identification No.) |
(Address of principal executive offices, including zip code)
(
(Registrant’s telephone number, including area code)
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
| Trading Symbol(s) |
| Name of each exchange on which registered |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated filer | ☐ | ☒ | Smaller reporting company | Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes
Number of shares outstanding of the issuer’s common stock as of the latest practicable date:
CELLECTAR BIOSCIENCES, INC.
FORM 10-Q INDEX
| 3 | |
|
|
|
5 | ||
|
|
|
5 | ||
Management’s Discussion and Analysis of Financial Condition and Results of Operations | 22 | |
32 | ||
|
|
|
34 | ||
|
|
|
34 | ||
34 | ||
35 |
FORWARD-LOOKING STATEMENTS
This quarterly report on Form 10-Q of Cellectar Biosciences, Inc. (the “Company”, “Cellectar”, “we”, “us”, “our”) contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, which we refer to as the Exchange Act. Examples of our forward-looking statements include:
● | our current views with respect to our business strategy, business plan and research and development activities; |
● | the progress of our product development programs, including clinical testing and the timing of commencement and results thereof; |
● | our projected operating results, including research and development expenses; |
● | our ability to continue development plans for iopofosine I 131 (iopofosine, also known as CLR 131), CLR 1900 series, CLR 2000 series and CLR 12120; |
● | our ability to continue development plans for our Phospholipid Drug Conjugates (PDC)™; |
● | our ability to maintain orphan drug designation in the U.S. for iopofosine as a therapeutic for the treatment of multiple myeloma, neuroblastoma, osteosarcoma, rhabdomyosarcoma, Ewing’s sarcoma and lymphoplasmacytic lymphoma, and the expected benefits of orphan drug status; |
● | any disruptions at our sole supplier of iopofosine; |
● | our ability to obtain additional funding via the sale of equity and/or debt securities, a strategic transaction or otherwise; |
● | our ability to advance our technologies into product candidates; |
● | our enhancement and consumption of current resources along with ability to obtain additional funding; |
● | our current view regarding general economic and market conditions, including our competitive strengths; |
● | uncertainty and economic instability resulting from conflicts, military actions, terrorist attacks, natural disasters, public health crises, including the occurrence of a contagious disease or illness such as the COVID-19 pandemic, cyber-attacks and general instability; |
● | the future impacts of legislative and regulatory developments in the United States on the pricing and reimbursement of our product candidates; |
● | our ability to meet the continued listing standards of Nasdaq; |
● | assumptions underlying any of the foregoing; and |
● | any other statements that address events or developments that we intend or believe will or may occur in the future. |
3
In some cases, you can identify forward-looking statements by terminology, such as “expects,” “anticipates,” “intends,” “estimates,” “plans,” “believes,” “seeks,” “may,” “should,” “could”, “would” or the negative of such terms or other similar expressions. Accordingly, these statements involve estimates, assumptions and uncertainties that could cause actual results to differ materially from those expressed in them. Forward-looking statements also involve risks and uncertainties, many of which are beyond our control. Any forward-looking statements are qualified in their entirety by reference to the factors discussed throughout this quarterly report.
You should read this report completely and with the understanding that our actual future results may be materially different from what we expect. You should assume that the information appearing in this report is accurate as of the date hereof only. Because the risk factors referred to herein could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.
This quarterly report on Form 10-Q contains trademarks and service marks of Cellectar Biosciences, Inc. Unless otherwise provided in this quarterly report on Form 10-Q, trademarks identified by ™ are trademarks of Cellectar Biosciences, Inc. All other trademarks are the property of their respective owners.
4
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
CELLECTAR BIOSCIENCES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
September 30, | December 31, | |||||
| 2024 |
| 2023 | |||
ASSETS |
|
|
|
| ||
CURRENT ASSETS: |
|
|
|
| ||
Cash and cash equivalents | $ | |
| $ | | |
Prepaid expenses and other current assets |
| |
| | ||
Total current assets |
| |
|
| | |
Property, plant & equipment, net |
| |
|
| | |
Operating lease right-of-use asset |
| |
|
| | |
Other long-term assets |
| | | |||
TOTAL ASSETS | $ | |
| $ | | |
|
| |||||
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) |
|
|
|
| ||
CURRENT LIABILITIES: |
|
|
|
| ||
Accounts payable and accrued liabilities | $ | |
| $ | | |
Warrant liability | |
| | |||
Lease liability, current |
| |
| | ||
Total current liabilities |
| |
| | ||
Long-term lease liability, net of current portion |
| |
| | ||
TOTAL LIABILITIES | | | ||||
COMMITMENTS AND CONTINGENCIES (Note 7) |
|
| ||||
MEZZANINE EQUITY: |
|
|
|
| ||
Series D preferred stock, |
| | | |||
STOCKHOLDERS’ EQUITY (DEFICIT): | ||||||
Series E-2 preferred stock, |
| |
|
| | |
Series E-3 preferred stock, |
| |
| — | ||
Series E-4 preferred stock, | | — | ||||
Common stock, $ |
| |
| | ||
Additional paid-in capital |
| |
|
| | |
Accumulated deficit |
| ( |
| ( | ||
Total stockholders’ equity (deficit) | | ( | ||||
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | $ | | $ | |
The accompanying notes are an integral part of these condensed consolidated financial statements.
5
CELLECTAR BIOSCIENCES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||
| 2024 |
| 2023 |
| 2024 |
| 2023 | |||||
OPERATING EXPENSES: |
|
|
|
|
|
|
| |||||
Research and development | $ | | $ | | $ | | $ | | ||||
General and administrative |
| |
| |
| |
| | ||||
Total operating expenses |
| |
| |
| |
| | ||||
LOSS FROM OPERATIONS |
| ( |
| ( |
| ( |
| ( | ||||
OTHER INCOME (EXPENSE): |
|
|
|
| ||||||||
Warrant issuance expense | ( | ( | ( | ( | ||||||||
Gain (loss) on valuation of warrants | | ( | | ( | ||||||||
Interest income |
| |
| |
| |
| | ||||
Total other expense |
| ( |
| ( |
| ( |
| ( | ||||
NET LOSS | $ | ( | $ | ( | ( | $ | ( | |||||
NET LOSS PER SHARE — BASIC | $ | ( | $ | ( | ( | $ | ( | |||||
NET LOSS PER SHARE — DILUTED | $ | ( | $ | ( | ( | $ | ( | |||||
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING — BASIC | | | | | ||||||||
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING — DILUTED |
| |
| |
| |
| |
The accompanying notes are an integral part of these condensed consolidated financial statements.
6
CELLECTAR BIOSCIENCES, INC.
CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)
(Unaudited)
Series D Preferred | Total | ||||||||||||||||||||||||
Stock | Preferred Stock | Common Stock | Additional | Accumulated | Stockholders’ | ||||||||||||||||||||
| Shares |
| Amount |
|
| Shares |
| Amount |
| Shares |
| Par Amount |
| Paid-In Capital |
| Deficit |
| (Deficit) Equity | |||||||
Balance at December 31, 2022 |
| | $ | | — | $ | — | | $ | | $ | | $ | ( | $ | | |||||||||
Conversion of pre-funded warrants into common stock |
| — | — | — | — | | | — | — | | |||||||||||||||
Stock-based compensation | — | — | — | — | — | — | | — | | ||||||||||||||||
Net loss | — | — | — | — | — | — | — | ( | ( | ||||||||||||||||
Balance at March 31, 2023 | | | — | — | | | | ( | | ||||||||||||||||
Stock-based compensation |
| — | — | — | — | — | — | | — | | |||||||||||||||
Net loss | — | — | — | — | — | — | — | ( | ( | ||||||||||||||||
Balance at June 30, 2023 |
| | | — | — | | | | ( | ( | |||||||||||||||
Issuance of Series E-1 preferred stock, net of issuance costs (Note 6) | | | — | — | — | — | — | — | — | ||||||||||||||||
Stock-based compensation | — | — | — | — | — | — | | — | | ||||||||||||||||
Exercise of warrants into common stock | — | — | — | — | | | | — | | ||||||||||||||||
Reclassification of pre-funded warrants to liability | — | — | — | — | — | — | ( | — | ( | ||||||||||||||||
Net loss | — | — | — | — | — | — | — | ( | ( | ||||||||||||||||
Balance at September 30, 2023 | | $ | | — | $ | — | | $ | | $ | | $ | ( | $ | ( | ||||||||||
| |||||||||||||||||||||||||
Balance at December 31, 2023 | | $ | | | $ | | | $ | | $ | | $ | ( | $ | ( | ||||||||||
Stock-based compensation | — | — | — | — | — | — | | — | | ||||||||||||||||
Conversion of pre-funded warrants into common shares | — | — | — | — | | | | — | | ||||||||||||||||
Exercise of warrants for preferred stock, net of issuance costs (Note 2) | — | — | | | — | — | — | — | | ||||||||||||||||
Conversion of Series E-3 preferred stock into common stock | — | — | ( | ( | | | | — | — | ||||||||||||||||
Exercise of warrants for common stock | — | — | — | — | | | | — | | ||||||||||||||||
Conversion of Series E-2 preferred stock into common stock |
| — | — | ( | ( | | | | — | — | |||||||||||||||
Retired shares | — | — | — | — | ( | — | — | — | — | ||||||||||||||||
Net loss | — | — | — | — | — | — | — | ( | ( | ||||||||||||||||
Balance at March 31, 2024 | | | | | | | | ( | | ||||||||||||||||
Stock-based compensation | — | — | — | — | — | — | | — | | ||||||||||||||||
Conversion of Series E-3 preferred stock into common stock | — | — | ( | ( | | | | — | — | ||||||||||||||||
Net loss |
| — | — | — | — | — | — | — | ( | ( | |||||||||||||||
Balance at June 30, 2024 | | $ | | | $ | | | $ | | $ | | $ | ( | $ | | ||||||||||
Stock-based compensation | | — | | ||||||||||||||||||||||
Issuance of E-4 preferred stock net of issuance costs | — | — | | | — | — | — | — | | ||||||||||||||||
Conversion of Series E-2 preferred stock into common stock | — | — | ( | ( | | | | — | — | ||||||||||||||||
Conversion of Series E-4 preferred stock into common stock | — | — | ( | ( | | | | — | — | ||||||||||||||||
Stock option exercise into common stock | — | — | — | — | | — | — | — | — | ||||||||||||||||
Net loss | — | — | — | — | — | — | — | ( | ( | ||||||||||||||||
Balance at September 30, 2024 |
| | $ | | | $ | | | $ | | $ | | $ | ( | $ | |
The accompanying notes are an integral part of these condensed consolidated financial statements.
7
CELLECTAR BIOSCIENCES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
Nine Months Ended | ||||||
September 30, | ||||||
|
| 2024 |
| 2023 | ||
CASH FLOWS FROM OPERATING ACTIVITIES: |
|
|
|
| ||
Net loss | $ | ( |
| $ | ( | |
Adjustments to reconcile net loss to cash used in operating activities: |
|
|
| |||
Depreciation and amortization |
| |
|
| | |
Stock-based compensation expense |
| |
|
| | |
Warrant issuance expense | | | ||||
Change in operating lease right-of-use asset |
| | | |||
Change in fair value of warrants |
| ( |
|
| | |
Changes in: | ||||||
Prepaid expenses and other current assets | ( | ( | ||||
Lease liability |
| ( |
| ( | ||
Accounts payable and accrued liabilities |
| ( |
|
| | |
Cash used in operating activities |
| ( |
|
| ( | |
CASH FLOWS FROM INVESTING ACTIVITIES: |
|
|
| |||
Purchases of property, plant & equipment |
| ( | ( | |||
Cash used in investing activities |
| ( |
|
| ( | |
CASH FLOWS FROM FINANCING ACTIVITIES: |
|
| ||||
Proceeds from issuance of preferred stock and warrants, net of issuance costs |
| — |
|
| | |
Proceeds from exercise of warrants, net of issuance costs | | | ||||
Cash provided by financing activities | | | ||||
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | | ( | ||||
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD |
| |
|
| | |
CASH AND CASH EQUIVALENTS AT END OF PERIOD | $ | | $ | | ||
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION | ||||||
Settlement of warrants to equity | $ | | $ | — | ||
Conversion of preferred stock to common stock | $ | | $ | — |
The accompanying notes are an integral part of these condensed consolidated financial statements.
8
CELLECTAR BIOSCIENCES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
1. NATURE OF BUSINESS AND ORGANIZATION
Cellectar Biosciences, Inc. (the Company) is a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, leveraging the Company’s proprietary phospholipid drug conjugate™ (PDC™) delivery platform that specifically targets cancer cells and delivers improved efficacy and better safety as a result of fewer off-target effects.
Going Concern — As an emerging growth company, the Company has, by design, incurred significant recurring losses and used net cash in its operations since its inception as it devotes substantially all of its efforts towards researching, developing and seeking approval for its product candidates to be commercialized in the marketplace. As a result of these efforts, the Company had an accumulated deficit of approximately $
To fund its research, development, and approval efforts, the Company has been heavily dependent on funding from private investors and public stockholders since its inception through the issuance of securities, such as common stock, convertible preferred stock, and warrants (outside capital). The Company expects to remain heavily dependent on outside capital to fund the Company’s operations for the foreseeable future until such time that one or more of its product candidates are approved and successfully commercialized in the marketplace. While management believes additional outside capital will be secured as needed, no assurance can be provided that additional outside capital will be secured, or secured on terms that are acceptable to the Company.
As of the date the accompanying consolidated financial statements were issued (the “issuance date”), the Company’s available liquidity to fund the Company’s operations over the next twelve months beyond the issuance date was limited to approximately $
These uncertainties raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements have been prepared on the basis that the Company will continue to operate as a going concern, which contemplates it will be able to realize assets and settle liabilities and commitments in the normal course of business for the foreseeable future. Accordingly, the accompanying consolidated financial statements do not include any adjustments that may result from the outcome of these uncertainties.
The condensed consolidated financial statements have been prepared by Cellectar Biosciences, Inc. in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Management believes the disclosures made in this document are adequate with respect to interim reporting requirements.
9
The accompanying Condensed Consolidated Balance Sheet as of December 31, 2023, has been derived from the Company’s audited financial statements. The accompanying Condensed Consolidated Balance Sheet as of September 30, 2024, and the Condensed Consolidated Statements of Operations, Cash Flows, and the Consolidated Statements of Stockholders’ Equity for the nine months ended September 30, 2024 and 2023, and the related interim information contained within the Notes to the Condensed Consolidated Financial Statements, have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) for interim financial information and with the instructions, rules and regulations of the Securities and Exchange Commission (SEC) for interim financial information. Accordingly, they do not include all the information and the notes required by U.S. GAAP for complete financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments which are of a nature necessary for the fair presentation of the Company’s consolidated financial position as of September 30, 2024, and consolidated results of its operations, cash flows, and stockholders’ equity for the nine months ended September 30, 2024 and 2023. The results for the nine months ended September 30, 2024, are not necessarily indicative of future results.
These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto included in the Company’s Form 10-K/A for the fiscal year ended December 31, 2023, which was filed with the SEC on October 29, 2024.
Use of Estimates — The preparation of the accompanying consolidated financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. Significant estimates include the assumptions used in the accrual for potential liabilities, the valuation of the warrant liability, the valuation of debt and equity instruments, the valuation of stock options issued for services, and deferred tax valuation allowances. Actual results could differ from those estimates.
Property, Plant & Equipment — Property, plant & equipment are stated at cost. Depreciation is provided using the straight-line method over the estimated useful lives of the assets (
Right-of-Use (ROU) Asset and Lease Liabilities -The Company accounts for all material leases in accordance with FASB Accounting Standards Codification (ASC) Topic 842, Leases. ROU Assets are amortized over their estimated useful life, which represents the full term of the lease. See Note 8.
Stock-Based Compensation — The Company uses the Black-Scholes option-pricing model to calculate the grant-date fair value of stock option awards. The resulting compensation expense, net of forfeitures for awards that are not performance-based, is recognized on a straight-line basis over the service period of the award, which in the three and nine months ended September 30, 2024 and 2023, ranged from
Research and Development — Research and development costs are expensed as incurred. The Company recognizes revenue and cost reimbursements from government grants when it is probable that the Company will comply with the conditions attached to the grant arrangement and the grant proceeds will be received. Government grants are recognized on a systematic basis over the periods in which the Company recognizes the related costs for which the government grant is intended to compensate. Specifically, when government grants are related to reimbursements for cost of revenues or operating expenses, the government grants are recognized as a reduction of the related expense in the Condensed Consolidated Statements of Operations. The Company records government grants receivable in the Condensed Consolidated Balance Sheets in prepaid expenses and other current assets.
10
Income Taxes — Income taxes are accounted for using the liability method of accounting. Under this method, deferred tax assets and liabilities are determined based on temporary differences between the financial statement basis and tax basis of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established when it is more-likely-than-not that some portion of the deferred tax assets will not be realized. Management has provided a full valuation allowance against the Company’s gross deferred tax asset. Tax positions taken or expected to be taken in the course of preparing tax returns are required to be evaluated to determine whether the tax positions are more-likely-than-not to be sustained by the applicable tax authority. Tax positions deemed not to meet a more-likely-than-not threshold would be recorded as tax expense in the current year. There are no uncertain tax positions that require accrual to or disclosure in the financial statements as of September 30, 2024 and December 31, 2023.
Fair Value of Financial Instruments — The guidance under ASC Topic 825, Financial Instruments, requires disclosure of the fair value of certain financial instruments. Financial instruments in the accompanying financial statements consist of cash equivalents, prepaid expenses and other assets, accounts payable and accrued liabilities, and long-term obligations. The carrying amount of cash equivalents, prepaid expenses, other current assets and accounts payable approximate their fair value as a result of their short-term nature. (See Notes 2 and 3)
Warrants — The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in ASC 480, Distinguishing Liabilities from Equity and ASC 815, Derivatives and Hedging. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common stock and whether the warrant holders could potentially require net cash settlement in a fundamental transaction outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding (see Note 2). If the warrants are liability-classified, valuation changes, as well as the cost to issue the warrants, are included in Other Income (Expense) in the financial statements (see Note 3). If these instruments are initially classified as either liabilities or equity and a subsequent assessment determines that the classification has changed, the Company reflects that change in the financial statements.
Preferred Stock — The Company accounts for preferred stock based upon their specific terms and the authoritative guidance in ASC 480 and ASC 815, including whether they are freestanding instruments, whether any redemption or conversion aspects exist and how they are required to be settled (particularly if there is a cash settlement aspect), whether they contain characteristics that are predominantly debt-like or equity-like, whether they have embedded derivatives, and if they have redemption features. Based upon analysis of these criteria, the preferred stock will be classified as either debt, temporary (or “mezzanine”) equity, or permanent equity. The resultant classification is then evaluated quarterly to determine whether any change to the classification is required.
Concentration of Credit Risk — Financial instruments that subject the Company to credit risk consist of cash and cash equivalents on deposit with financial institutions. The Company’s excess cash as of September 30, 2024 and December 31, 2023 is on deposit in interest-bearing accounts with well-established financial institutions. At times, such amounts may exceed the FDIC insurance limits. As of September 30, 2024, and December 31, 2023, uninsured cash balances totaled approximately $
Government Assistance — Reimbursements of eligible expenditures pursuant to government assistance programs are recorded as reductions of operating costs when there is reasonable assurance that the Company will comply with the conditions attached to the grant arrangement and when the reimbursement has been claimed. The determination of the amount of the claim, and accordingly the receivable amount, requires management to make calculations based on its interpretation of eligible expenditures in accordance with the terms of the programs. The reimbursement claims submitted by the Company are subject to review by the relevant . The Company currently has a cancer treatment research award through the National Cancer Institute (NCI) totaling approximately $
11
During the nine months ended September 30, 2024 and 2023, the Company received approximately $
Recently Adopted Accounting Pronouncements Not Yet Adopted — In December 2023, the FASB issued Accounting Standards Update (ASU) No. 2023-09, Income Taxes (Topic 740)—Improvements to Income Tax Disclosures, which is intended to enhance the transparency and decision usefulness of income tax disclosures. Public business entities are required to adopt this standard for annual fiscal periods beginning after December 15, 2024, and early adoption is permitted. The Company is evaluating the impact the adoption of this guidance will have on its consolidated financial statements and related disclosures.
In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280). The amendments in this update expand segment disclosure requirements, including new segment disclosure requirements for entities with a single reportable segment among other disclosure requirements. This update is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact that the adoption of ASU 2023 - 07 will have on its condensed consolidated financial statements.
In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. The amendments in ASU 2024-03 address investor requests for more detailed expense information and require additional disaggregated disclosures in the notes to financial statements for certain categories of expenses that are included on the face of the income statement. This guidance is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating this guidance to determine the impact it may have on its condensed consolidated financial statements.
The Company evaluates all ASUs issued by the FASB for consideration of their applicability to the financial statements. The Company has assessed all ASUs issued but not yet adopted and concluded that those not disclosed are not relevant to the Company or are not expected to have a material impact.
Restatement of Previously Issued Consolidated Financial Statements — During the third quarter of 2024 the Company determined that it was necessary to re-evaluate its accounting treatment for certain previously issued warrants and preferred stock. Additionally, the Company identified certain operating costs previously presented as research and development expenses which are more appropriately classified as general and administrative. In accordance with Staff Accounting Bulletins No. 99 (SAB No. 99) Topic 1.M, “Materiality” and SAB No. 99 Topic 1.N “Considering the Effects of Misstatements when Quantifying Misstatements in the Current Year Financial Statements,” the Company assessed the materiality of these errors to its previously issued consolidated financial statements. Based upon the Company’s evaluation of both quantitative and qualitative factors, the Company concluded the errors were material to the Company’s previously issued consolidated financial statements for the fiscal years ended December 31, 2023 and 2022, as well as those for the first quarter of 2024. Accordingly, this Form 10-Q presents the Company’s Restated Condensed Consolidated Financial Statements for the three and nine months ended September 30, 2023 as reflected in the Company’s Form 10-K/A for the year ended December 31, 2023.
2. STOCKHOLDERS’ EQUITY
July 2024 Warrant Inducement
On July 21, 2024, the Company, entered into a warrant exercise inducement (the “Inducement”) with certain holders of its September 2023 Tranche B warrants, pursuant to which the holders agreed to exercise the warrants to purchase
The Inducement Warrants have the following terms:
● | The 2024 Tranche A warrants have an exercise price of $ |
12
● | The 2024 Tranche B warrants have an exercise price of $ |
● | The 2024 Tranche C warrants have an exercise price of $ |
Due to a cash settlement feature that requires cash settlement in event of a fundamental transaction that is outside the Company’s control resulting in a form of settlement inconsistent with that which would be received by other security holders, the warrants do not qualify under the equity classification guidance. As a result, and in accordance with the guidance in ASC 815, the warrants issued in July 2024 are deemed to be liabilities. All such liabilities are required to be presented at fair value, with changes reflected in financial results for the period. See Note 3 for the related valuation.
In accordance with the guidance above, the Company recorded the Inducement Warrants and preferred stock at their respective fair values. Utilizing valuation techniques described in Note 3 below, the Company computed the fair value of the Inducement Warrants as $
Subsequent to the issuance of the Series E-4 preferred stock and prior to September 30, 2024, investors who held
September 2023 Private Placement
On September 8, 2023, in a private placement with certain institutional investors, the Company issued
The conversion prices for the preferred stock are as follows: for the Series E-1 or E-2 preferred stock, $
● | Tranche A warrants, for an aggregate exercise price of $ |
● | Tranche B warrants, for an aggregate exercise price of $ |
As of December 31, 2023, the Tranche A and Tranche B warrants did not qualify as derivatives; however, they did not meet the requirements necessary to be considered indexable in the Company’s stock. As a result, and in accordance with the guidance in FASB ASC 815, the warrants were deemed to be liabilities. As of September 30, 2024, the Tranche B warrants do not qualify as derivatives and meet the requirements necessary to be considered indexable in the Company’s stock. However, due to a cash settlement feature that requires cash settlement in event of a fundamental transaction that is outside the Company’s control resulting in a form of settlement inconsistent with that which would be received by other security holders, the warrants do not qualify under the equity classification guidance. As a result, and in accordance with the guidance in ASC 815, the Tranche B warrants continue to be deemed
13
liabilities. All such liabilities are required to be presented at fair value, with changes reflected in financial results for the period. As discussed above, the majority of the Tranche B warrants were exercised in July 2024. See Note 3 for the related valuation.
When issued, the Series E-1 preferred stock had a redemption feature; therefore, it was classified as mezzanine equity as of September 30, 2023. The Series E-1 preferred stock also had a liquidation preference, which was calculated as an amount per share equal to the greater of (i) two times (2X) the Original Per Share Price, together with any declared, unpaid dividends, or (ii) such amount per share as would have been payable had all shares of Series E-1 preferred stock been converted into Common Stock immediately prior to such Liquidation. While the Series E-1 preferred was outstanding, this resulted in both the Tranche A and Tranche B warrants being considered puttable by virtue of the liquidation preference impacting the disposition of these warrants in the event of a liquidation. In accordance with the guidance in ASC 480, a puttable warrant is deemed to be a liability. These features only applied to the Series E-1 preferred stock when it was outstanding; upon stockholder approval of the transaction, which was obtained by the Company at a special meeting of stockholders held on October 25, 2023, the Series E-1 preferred stock immediately converted into either Series E-2 preferred stock and/or common stock, dependent upon the beneficial ownership position of the holder.
The net proceeds from the September 2023 Private Placement were allocated first to the fair value of the Tranche A and Tranche B warrants, which had a fair value upon issuance of $
Series E preferred stock is convertible to common stock at the request of the holder, subject to the holder not exceeding certain beneficial ownership percentages as stipulated in the financing agreement. Subsequent to the issuance of the Series E-2 preferred stock and prior to December 31, 2023, preferred holders converted
During the nine months ended September 30, 2024,
In January 2024, the Company released topline data from its pivotal, Phase 2b CLOVER WaM trial. In accordance with the terms of the Tranche A warrant, the warants’ expiration accelerated to
During the nine months ended September 30, 2024, investors who held
October 2022 Public Offering and Private Placement
On October 25, 2022, the Company completed a registered direct offering of
During the nine months ended September 30, 2024,
14
Warrants
The following table summarizes information with regard to outstanding warrants to purchase stock as of September 30, 2024:
Number of Common | ||||||||
Shares Issuable |
| |||||||
Upon Exercise of |
| |||||||
Outstanding | Exercise |
| ||||||
Offering |
| Warrants |
| Price |
| Expiration Date | ||
2024 Tranche A Warrants | | $ | ||||||
2024 Tranche B Warrants | | $ | ||||||
2024 Tranche C Warrants | | $ | ||||||
2023 Tranche B Preferred Warrants | | $ | ||||||
2022 Common Warrants | | $ | ||||||
June 2020 Series H Common Warrants | | $ | ||||||
October 2017 Series D Common Warrants | | $ |
| |||||
Total |
| |
|
|
|
|
All warrants in the table above are liability-classified.
3. FAIR VALUE
In accordance with the Fair Value Measurements and Disclosures Topic of ASC 820, the Company groups its financial assets and financial liabilities generally measured at fair value in three levels, based on the markets in which the assets and liabilities are traded, and the reliability of the assumptions used to determine fair value:
● | Level 1: Input prices quoted in an active market for identical financial assets or liabilities. |
● | Level 2: Inputs other than prices quoted in Level 1, such as prices quoted for similar financial assets and liabilities in active markets, prices for identical assets, and liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data. |
● | Level 3: Input prices quoted that are significant to the fair value of the financial assets or liabilities which are not observable or supported by an active market. |
To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The carrying value of cash and cash equivalents approximates fair value as maturities are less than three months. The carrying amounts reported for other current financial assets and liabilities approximate fair value because of their short-term nature. As of September 30, 2024, the Company does
15
July 2024 Warrants
As part of the July 2024 financing the Company issued Tranche A, B, and C warrants (the 2024 Warrants) to purchase shares of common stock (see Note 2). The fair value of the 2024 warrants was determined using a probability-weighted expected return method (PWERM) with a scenario-based Monte Carlo simulation and Black-Scholes model. The PWERM is a scenario-based methodology that estimates the fair value of the Company’s different classes of equity based upon an analysis of future values for the Company, assuming various outcomes. Under both models, assumptions and estimates are used to value the warrants. The Company assesses these assumptions and estimates on a quarterly basis as additional information that impacts the assumptions is obtained. The quantitative elements associated with the inputs impacting the fair value measurement of the 2024 Warrants include the value per share of the underlying common stock, the timing, form and overall value of the expected exits for the stockholders, the risk-free interest rate, the expected dividend yield and the expected volatility of the Company’s shares. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve for time periods approximately equal to the remaining contractual term of the warrants. The Company estimated a
The 2024 Warrants are classified within the Level 3 hierarchy because of the nature of these inputs and the valuation technique utilized, and had a fair value of $
The following table summarizes the modified option-pricing assumptions used on September 30, 2024 and December 31, 2023:
| July 21, |
| September 30, |
| |
2024 | 2024 |
| |||
Volatility |
| % | % | ||
Risk-free interest rate |
| % | % | ||
Expected life (years) |
|
| |||
Dividend |
| | % | | % |
September 2023 Warrants
As part of the September 2023 financing (see Note 2) the Company issued Tranche A and Tranche B warrants (the 2023 Warrants) to purchase shares of preferred stock which, on an as-converted basis, represented an aggregate of
As previously described, all of the Tranche A warrants were exercised in January 2024. Additionally, in July 2024, the holders of the Tranche B warrants exercised all but
The 2023 Warrants are classified within the Level 3 hierarchy because of the nature of these inputs and the valuation technique utilized, and had a fair value of $
16
The following table summarizes the modified option-pricing assumptions used on September 30, 2024 and December 31, 2023:
| September 30, |
| December 31, | ||
2024 | 2023 | ||||
Volatility | % | % | |||
Risk-free interest rate |
| | % | % | |
Expected life (years) |
| ||||
Dividend |
| | % | | % |
At the time the Tranche A warrants were exercised, their fair value, calculated as the difference between the common stock conversion rate in the Series E-3 preferred stock and the trading price of the stock when the warrants were exercised, was determined to be $
October 2022 Warrants
In October 2022 the Company issued a total of
The fair value of the 2022 Common Warrants was determined by utilizing a Black-Scholes option-pricing model. The quantitative elements associated with the inputs impacting the fair value measurement of the 2022 Common Warrants include the value per share of the underlying common stock, the risk-free interest rate, the expected dividend yield and the expected volatility of the Company’s shares. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve for time periods approximately equal to the remaining contractual term of the warrants. The Company estimated a
| September 30, |
| December 31, |
| |
2024 | 2023 | ||||
Volatility | | % | | % | |
Risk-free interest rate |
| | % | | % |
Expected life (years) |
| |
| | |
Dividend |
| | % | | % |
The following table summarizes the changes in the fair market value of the warrants which are classified within the Level 3 fair value hierarchy.
| Level 3 | ||
Fair value of Level 3 liabilities as of December 31, 2023 | $ | | |
Change in warrant fair value | ( | ||
Issuance of July 2024 Inducement Warrants | | ||
Settlement of 2023 Tranche A Warrants to equity | ( | ||
Settlement of 2023 Tranche B Warrants to equity | ( | ||
Exercise of October 2022 Warrants |
| ( | |
June 30, 2024, fair value of Level 3 liabilities | $ | |
17
4. STOCK-BASED COMPENSATION
Accounting for Stock-Based Compensation
2021 Stock Incentive Plans
The Company maintains the 2021 Stock Incentive Plan (the “2021 Plan”). The Company utilizes stock-based compensation incentives as a component of its employee and non-employee director and officer compensation philosophy. A committee of the Board of Directors determines the terms of the awards granted and may grant various forms of equity-based incentive compensation. Currently, these incentives consist principally of stock options and restricted shares. All outstanding awards under the 2015 Stock Incentive Plan (the “2015 Plan”) remained in effect according to the terms of the 2015 Plan. Any shares that are currently available under the 2015 Plan and any shares underlying 2015 Plan awards which are forfeited, cancelled, reacquired by the Company or otherwise terminated are added to the shares available for grant under the 2021 Plan.
Under the current stock option award program, all options become exercisable between one and three years after issuance and expire after ten years. The fair value of each stock option award is estimated on the grant date using the Black-Scholes option-pricing model. Volatility is based on the Company’s historical common stock volatility. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time. The expected term of stock options granted is based on an estimate of when options will be exercised in the future. Forfeitures are recorded as they occur. No dividends have been recorded historically.
At the annual meeting of stockholders held on June 14, 2024, the Company’s stockholders approved an increase in the number of shares of common stock available for issuance under the 2021 Stock Incentive Plan by
The following table summarizes amounts charged to expense for stock-based compensation related to employee and director stock option grants: